What question did this study set out to answer?

Evaluate the efficacy and safety of JMT108, a novel anti-PD-1/IL-15 fusion protein, in activating PD-1+ immune cells and its anti-tumor effects.

Novel Anti-PD-1/IL-15 Fusion Protein JMT108 Selectively Activates PD-1+ Immune Cells

View Full Paper

Ask AI

Bookmark

Evaluate the efficacy and safety of JMT108, a novel anti-PD-1/IL-15 fusion protein, in activating PD-1+ immune cells and its anti-tumor effects.
Developed JMT108 as a PD-1 targeted antibody-cytokine fusion protein.
Assessed immune cell proliferation in vitro using human PBMCs and activated T cells.
Evaluated in vivo selectivity in cynomolgus monkeys and hHSC reconstituted mice.
Tested anti-tumor activity in melanoma and hepatocellular carcinoma xenograft models.
Characterized pharmacokinetics and toxicity in cynomolgus monkeys.
JMT108 showed over 10,000 fold higher selectivity for PD-1+ T cells compared to N-803.
Reduced PD-1 expression on activated CD8+ T cells, unlike N-803 which led to upregulation.
Induced sustained expansion of PD-1+ CD8+ effector cells in hHSC-mice.
Demonstrated superior anti-tumor efficacy than anti-PD-1 antibodies in xenograft models.
Exhibited a favorable safety profile with minimal inflammatory cytokine induction in assays.

No takes yet. Share an insight, caveat, or question.

Findings reveal JMT108 enhances tumor immunity by selectively activating PD-1+ immune cells, suggesting improved cancer treatment options.

He et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark

Findings reveal JMT108 enhances tumor immunity by selectively activating PD-1+ immune cells, suggesting improved cancer treatment options.